Perrigo Co., of Allegan, Mich., is transferring the listing of its U.S.-traded common stock to the New York Stock Exchange (NYSE) from Nasdaq

Stemline Therapeutics Inc., of New York, said underwriters exercised in full their option to purchase an additional 620,689 shares of common stock at $14.50 each, generating an additional $9 million as part of the company's previously disclosed $60 million public offering

plc, of Dublin, Ireland, said its board on Thursday rejected New York-based Royalty Pharma's revised offer to acquire all of Elan's shares for $12.50 per share through its shell subsidiary Echo Pharma Acquisition Ltd., stating that the bid "grossly" undervalued the company

Pfizer Inc., of New York, said it intends to split off its remaining interest in Zoetis Inc., of Madison, N.J., the former animal health unit that recently completed its initial public offering

Oligomerix Inc., of New York, completed a $2.8M Series B financing, which included both the issuance of new convertible preferred shares and warrants...Stemline Therapeutics Inc., of New York, closed a public offering of 4,137,931 shares of common stock at $14.50 per share

New York-based Bristol-Myers Squibb Co.'s CTLA-4 blocker Yervoy (ipilimumab) won FDA clearance in April 2011 , and another drug given the nod that summer was the kinase inhibitor for patients with the BRAF V600E mutation, Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG). (See BioWorld Today, April 4, 2011, and Aug, 18, 2011.) It was those two approvals against which analysts weighed the chances of Thousand Oaks, Calif.-based Amgen Inc.'s talimogene laherparepvec, or T-VEC, brought

Acelrx Pharmaceuticals Inc., of Redwood City, Calif., reported top-line data that showed its sublingual Sufentanil NanoTab PCA (patient-controlled analgesia) System met the primary and secondary efficacy endpoints in a placebo-controlled, Phase III study. In the 48 hours following major orthopedic surgery, patients treated with sufentanil NanoTabs realized a significantly greater score in the Summed Pain Intensity Difference (SPID) than placebo-treated patients. Secondary endpoint data showed

A couple of hours later, it edged up further after New York-based Royalty Pharma upped its bid for the company

New York-based Pfizer said it would discontinue development of the drug in NHL after an independent data monitoring committee concluded during a scheduled interim analysis that the treatment would not meet the primary endpoint of improving overall survival compared with investigator's choice of bendamustine plus rituximab or gemcitabine plus rituximab

The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

The company was formed in 2008 through a management buyout of the active pharmaceutical ingredients business of Alpharma Inc. (now part of New York-based Pfizer Inc

A couple of hours later, it edged up further after New York-based Royalty Pharma upped its bid for the company

Most of Actavis' sales, at this point, derive from generic therapies, including major revenue generators such as those for New York-based Pfizer Inc.'s cholesterol-buster Lipitor (atorvastatin), and for Concerta (methylphenidate hydrochloride), the compound for attention-deficit and hyperactivity disorder from Johnson & Johnson, of New Brunswick, N.J

Intercept Pharmaceuticals Inc., of New York, reported initial results from OBADIAH, an ongoing Phase IIa trial of obeticholic acid (OCA) as a treatment for primary bile acid diarrhea (PBAD), showing that treatment with OCA is associated with statistically significant increased levels of fibroblast growth factor 19 (FGF19) and improvement in clinical symptoms in patients with PBAD

A couple of hours later, it edged up further after New York-based Royalty Pharma upped its bid for the company

Relmada Therapeutics Inc., of New York, retained Brio Financial Group and GBH CPAs PC as financial reporting consultant and audit firms, respectively, to prepare for a public listing

Inc. (Whitehouse Station, N.J.) Bristol-Myers Squibb Co. (New York) ND Nonexclusive deal to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus Merck will conduct the trial 4/23/13 Merck KGgA (Darmstadt, Germany) Pfizer Inc. (New York) ND Extended collaboration signed in 2002 by Merck's subsidiary EMD Serono Inc...Inc. (Whitehouse Station

it also gets research funding and royalties, while BMS holds onto worldwide rights 4/17/13 Tetragenetics Inc. (Cambridge, Mass.) Pfizer Inc. (New York) ND Deal with an option for an exclusive license with Pfizer using Tetragenetics' SionX application of its discovery platform Financial terms were not disclosed 4/4/13 X-BODY Biosciences Inc. (Waltham, Mass.) Jiangsu Hengrui Medicine Co...Merck gains worldwide commercialization rights and will pay royalties to Abide 5/3/13 Adaptive Biotechnologies

In 2007, the company inked a blockbuster deal with Pfizer Inc., of New York, focused on its Gene Expression Modulation by Small-molecules (GEMS) technology platform, which identifies small molecules that regulate post-transcriptional control mechanisms